Addition of Ceftriaxone and Amikacin to a Ciprofloxacin plus Metronidazole Regimen for Preventing Infectious Complications of Transrectal Ultrasound-Guided Prostate Biopsy: A Randomized Controlled Trial

IF 1.8 Q3 UROLOGY & NEPHROLOGY

Advances in Urology Pub Date : 2017-01-10 DOI:10.1155/2017/4635386

M. Izadpanahi, K. Nouri-Mahdavi, S. M. Majidi, M. Khorrami, F. Alizadeh, Mehrdad Mohammadi-Sichani

{"title":"Addition of Ceftriaxone and Amikacin to a Ciprofloxacin plus Metronidazole Regimen for Preventing Infectious Complications of Transrectal Ultrasound-Guided Prostate Biopsy: A Randomized Controlled Trial","authors":"M. Izadpanahi, K. Nouri-Mahdavi, S. M. Majidi, M. Khorrami, F. Alizadeh, Mehrdad Mohammadi-Sichani","doi":"10.1155/2017/4635386","DOIUrl":null,"url":null,"abstract":"Background. The objective of this study was to evaluate the efficacy of adding single doses of ceftriaxone and amikacin to a ciprofloxacin plus metronidazole regimen on the reduction of infectious complications following transrectal ultrasound-guided prostate biopsy (TRUS Bx). Materials and Methods. Four hundred and fifty patients who were candidates for TRUS Bx were divided into two groups of 225 each. The control group received ciprofloxacin 500 mg orally every 12 hours together with metronidazole 500 mg orally every 8 hours from the day prior to the procedure until the fifth postoperative day. In the second group, single doses of ceftriaxone 1 g by intravenous infusion and amikacin 5 mg/kg intramuscularly were administered 30–60 minutes before TRUS Bx in addition to the oral antimicrobials described for group 1. The incidence of infection was compared between the groups. Results. The incidence of infectious complications in the intervention group was significantly lower than that in the control group (4.6% versus 0.9%, p = 0.017). Conclusion. The addition of single doses of intramuscular amikacin and intravenously infused ceftriaxone to our prophylactic regimen of ciprofloxacin plus metronidazole resulted in a statistically significant reduction of infectious complications following TRUS Bx.","PeriodicalId":7490,"journal":{"name":"Advances in Urology","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2017-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4635386","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/4635386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background. The objective of this study was to evaluate the efficacy of adding single doses of ceftriaxone and amikacin to a ciprofloxacin plus metronidazole regimen on the reduction of infectious complications following transrectal ultrasound-guided prostate biopsy (TRUS Bx). Materials and Methods. Four hundred and fifty patients who were candidates for TRUS Bx were divided into two groups of 225 each. The control group received ciprofloxacin 500 mg orally every 12 hours together with metronidazole 500 mg orally every 8 hours from the day prior to the procedure until the fifth postoperative day. In the second group, single doses of ceftriaxone 1 g by intravenous infusion and amikacin 5 mg/kg intramuscularly were administered 30–60 minutes before TRUS Bx in addition to the oral antimicrobials described for group 1. The incidence of infection was compared between the groups. Results. The incidence of infectious complications in the intervention group was significantly lower than that in the control group (4.6% versus 0.9%, p = 0.017). Conclusion. The addition of single doses of intramuscular amikacin and intravenously infused ceftriaxone to our prophylactic regimen of ciprofloxacin plus metronidazole resulted in a statistically significant reduction of infectious complications following TRUS Bx.

查看原文本刊更多论文

在环丙沙星加甲硝唑方案中加入头孢曲松和阿米卡星预防经直肠超声引导前列腺活检感染性并发症的随机对照试验

背景。本研究的目的是评估在环丙沙星加甲硝唑方案中添加单剂量头孢曲松和阿米卡星对减少经直肠超声引导前列腺活检(TRUS Bx)后感染并发症的疗效。材料与方法。450例TRUS Bx候选患者分为两组，每组225例。对照组患者术前至术后第5天口服环丙沙星500 mg，每12小时口服一次，甲硝唑500 mg，每8小时口服一次。在第二组中，除了第1组所述的口服抗菌剂外，在TRUS Bx治疗前30-60分钟，静脉滴注单剂量头孢曲松1 g，肌注阿米卡星5 mg/kg。比较两组患者的感染发生率。结果。干预组感染并发症发生率明显低于对照组(4.6% vs 0.9%， p = 0.017)。结论。在环丙沙星加甲硝唑的预防方案中加入单剂量肌注阿米卡星和静脉滴注头孢曲松，可以显著减少TRUS Bx后的感染并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Urology UROLOGY & NEPHROLOGY-

CiteScore

2.90

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Urology is a peer-reviewed, open access journal that publishes state-of-the-art reviews and original research papers of wide interest in all fields of urology. The journal strives to provide publication of important manuscripts to the widest possible audience worldwide, without the constraints of expensive, hard-to-access, traditional bound journals. Advances in Urology is designed to improve publication access of both well-established urologic scientists and less well-established writers, by allowing interested scientists worldwide to participate fully.